Abstract
Letters and Corrections1 June 1990Busulfan and Veno-occlusive Disease of the LiverGilles Vassal, MD, Olivier Hartmann, MD, Ellen Benhamou, MDGilles Vassal, MDSearch for more papers by this author, Olivier Hartmann, MDSearch for more papers by this author, Ellen Benhamou, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-11-881_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:High-dose busulfan in combination therapy is well known to be responsible for veno-occlusive disease of the liver in about 20% of adult patients undergoing bone marrow transplantation (1, 2). However, the incidence of this disease is lower (0% to 5%) in children (3). In our institution, from September 1979 to December 1990, 403 courses of high-dose chemotherapy were administered before bone marrow transplantation in children with solid tumors: 125 courses included high-dose busulfan. Two total busulfan doses were used: 16 mg/kg body weight in 64 courses and 600 mg/m2body surface area in 61 courses. The dose...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
